Works matching IS 02698811 AND DT 2021 AND VI 35 AND IP 9

Results: 16

Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1081, doi. 10.1177/0269881121996890

By:

Kølbæk, Pernille;
Dines, David;
Holm, Tine;
Blicher, Anne B;
Sørensen, Rune D;
O'Leary, Kathrine M;
Feller, Sandra G;
Buus, Chanette W;
Nielsen, Cecilie M;
Opler, Mark;
Mors, Ole;
Correll, Christoph U;
Østergaard, Søren D

Publication type:

Article

Antipsychotics, the heartland of clinical psychopharmacology?

Published in:

2021

By:

Young, Allan H;
Jauhar, Sameer

Publication type:

Editorial

Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1111, doi. 10.1177/02698811211035391

By:

Wang, Yewei;
Wang, Dandan;
Cheng, Jie;
Fang, Xinyu;
Chen, Yan;
Yu, Lingfang;
Ren, Juanjuan;
Tian, Yuan;
Zhang, Chen

Publication type:

Article

Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review.

Published in:

2021

By:

Besag, Frank MC;
Vasey, Michael J;
Lao, Kim SJ;
Chowdhury, Uttom;
Stern, Jeremy S

Publication type:

Literature Review

Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1141, doi. 10.1177/02698811211029739

By:

Meighan, Wayne;
Elston, Thomas W;
Bilkey, David;
Ward, Ryan D

Publication type:

Article

Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1074, doi. 10.1177/02698811211029738

By:

Forte, Alberto;
Pompili, Maurizio;
Imbastaro, Benedetta;
De Luca, Gabriele Pasquale;
Mastrangelo, Martina;
Montalbani, Benedetta;
Baldessarini, Ross J

Publication type:

Article

Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1152, doi. 10.1177/02698811211029737

By:

Béchard, Laurent;
Corbeil, Olivier;
Plante, Maude;
Thivierge, Marc-André;
Lafrenière, Charles-Émile;
Roy, Marc-André;
Demers, Marie-France

Publication type:

Article

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1030, doi. 10.1177/02698811211026456

By:

Reynolds, Gavin P

Publication type:

Article

Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1120, doi. 10.1177/02698811211026450

By:

Onen, Sinay;
Taymur, Ibrahim

Publication type:

Article

Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review.

Published in:

2021

By:

de Filippis, Renato;
Soldevila-Matías, Pau;
Guinart, Daniel;
De Fazio, Pasquale;
Rubio, Jose M;
Kane, John M;
Schoretsanitis, Georgios

Publication type:

Literature Review

Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1091, doi. 10.1177/02698811211009794

By:

Wallman, Phoebe;
Clark, Ivana;
Taylor, David

Publication type:

Article

Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1134, doi. 10.1177/02698811211008592

By:

Avrahami, Matan;
Peskin, Miriam;
Moore, Tyler;
Drapisz, Adi;
Taylor, Jerome;
Segal-Gavish, Hadar;
Balan-Moshe, Livia;
Shachar, Issac;
Levy, Tomer;
Weizman, Abraham;
Barzilay, Ran

Publication type:

Article

Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1127, doi. 10.1177/02698811211003477

By:

Hommers, Leif;
Scherf-Clavel, Maike;
Stempel, Roberta;
Roth, Julian;
Falter, Matthias;
Deckert, Jürgen;
Mattheisen, Manuel;
Unterecker, Stefan;
Gawlik, Micha

Publication type:

Article

Individualizing tapering antipsychotic schemes considering D2 blockade dynamics.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1161, doi. 10.1177/02698811211000780

By:

Costardi, Carlos G;
Gadelha, Ary;
Bressan, Rodrigo A

Publication type:

Article

Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1099, doi. 10.1177/02698811211000778

By:

Livingston, Nicholas R;
Hawkins, Peter CT;
Gilleen, James;
Ye, Rong;
Valdearenas, Lorena;
Shergill, Sukhi S;
Mehta, Mitul A

Publication type:

Article

Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?

Published in:

Journal of Psychopharmacology, 2021, v. 35, n. 9, p. 1158, doi. 10.1177/02698811211000773

By:

Papanastasiou, Evangelos;
Shergill, Sukhwinder S

Publication type:

Article